Our observations here show that genetic and pharmacological interventions targeted toward HDAC6 ameliorated the elevated levels of TGF‐β1, p‐Smad2/3, Nkx‐2.5 and p‐Erk1/2 in CFs. The gene discussed is SMAD2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.